| 1 | 5 ASA, enemas, suppositories, corticosteroids | - | - | - | - | [1] 97 97 💬
|
| 2 | ACEI/ARB and corticosteroids | - | - | - | - | [1] 66 66 💬
|
| 3 | Azithromycin + N-acetylcystein + inhaled corticosteroid | [1] Azithromycin Azithromycin | [2] Azithromycin
Azithromycin
,
Azithromycin
💬
| - | - | [1] 228 228 💬
|
| 4 | Chronic Corticosteroid Therapy | - | - | - | - | [1] 113 113 💬
|
| 5 | Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids | [1] Rituximab Rituximab | [1] Rituximab
Rituximab
💬
| [1] MS4A1 MS4A1 💬
| [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 85 85 💬
|
| 6 | Corticosteroid | - | - | - | - | [9] 13 13, 42, 43, 44, 45, 66, 96, 97, 222 💬
|
| 7 | Corticosteroid (CS) | - | - | - | - | [1] 41 41 💬
|
| 8 | Corticosteroid and azathioprine | [1] Azathioprine Azathioprine | [1] Azathioprine
Azathioprine
💬
| - | - | [4] 42 42, 43, 44, 45 💬
|
| 9 | Corticosteroid and non-biological agents. | - | - | - | - | [1] 46 46 💬
|
| 10 | Corticosteroid or NSAID | - | - | - | - | [1] 46 46 💬
|
| 11 | Corticosteroid treatment (Methylprednisolone or prednisolone) | [2] Methylprednisolone Methylprednisolone, Prednisolone | [2] Methylprednisolone
Methylprednisolone
,
Prednisolone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 64 64 💬
|
| 12 | Corticosteroids | - | - | - | - | [12] 41 41, 46, 49, 63, 64, 97, 107, 113, 164, 220, 296, 300 💬
|
| 13 | Corticosteroids & tanCART19/20 | - | - | - | - | [1] 13 13 💬
|
| 14 | Corticosteroids (Aprednislon) | - | - | - | - | [1] 63 63 💬
|
| 15 | Corticosteroids (prednisone or prednisolone) | [2] Prednisolone Prednisolone, Prednisone | [2] Prednisolone
Prednisolone
,
Prednisone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 49 49 💬
|
| 16 | Corticosteroids +immune suppressive +amino salicylic acid | [1] Salicylic acid Salicylic acid | [1] Salicylic acid
Salicylic acid
💬
| - | - | [1] 97 97 💬
|
| 17 | Corticosteroids for Systemic Use | - | - | - | - | [1] 41 41 💬
|
| 18 | Corticosteroids only | - | - | - | - | [1] 97 97 💬
|
| 19 | Corticosteroids'therapy | - | - | - | - | [1] 35 35 💬
|
| 20 | CS (corticosteroids) Only | - | - | - | - | [1] 97 97 💬
|
| 21 | Cumulative corticosteroid exposure | - | - | - | - | [1] 49 49 💬
|
| 22 | H02 - Corticosteroidi Sistemici | - | - | - | - | [1] 299 299 💬
|
| 23 | Intra-articular corticosteroid injection | - | - | - | - | [1] 46 46 💬
|
| 24 | IV Corticosteroid | - | - | - | - | [1] 97 97 💬
|
| 25 | Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone | [2] Mesalazine Mesalazine, Methylprednisolone | [2] Mesalamine
Mesalamine
,
Methylprednisolone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 97 97 💬
|
| 26 | Oral corticosteroids | - | - | - | - | [5] 13 13, 46, 97, 171, 251 💬
|
| 27 | Oral corticosteroids (OCS) | - | - | - | - | [1] 162 162 💬
|
| 28 | Prophylactic Corticosteroid Taper Regimen | - | - | - | - | [1] 251 251 💬
|
| 29 | Reactive Corticosteroid Taper Regimen | - | - | - | - | [1] 251 251 💬
|
| 30 | Rituximab, Cyclophosphamide, and Corticosteroids | [2] Cyclophosphamide Cyclophosphamide, Rituximab | [3] Cyclophosphamide
Cyclophosphamide
,
Rituximab
,
Cyclophosphamide
💬
| [1] MS4A1 MS4A1 💬
| [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 222 222 💬
|
| 31 | Treatment with topical superpotent corticosteroid therapy | - | - | - | - | [1] 162 162 💬
|
| 32 | Valproid acid plus corticosteroids | - | - | - | - | [1] 26 26 💬
|